Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Triple Negative Breast Neoplasms

NCT07198321 2025-09-30

A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors

Phase 1/2 Not yet recruiting

450 enrolled

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT07180576 2025-09-18

FORCE

Phase 1/2 Not yet recruiting

15 enrolled

Head & Neck

Head and Neck Neoplasms, Neoplasms, Sarcopenia

NCT07064863 2025-07-17

BCG-TIME

Phase 1/2 Not yet recruiting

31 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

NCT07032142 2025-06-22

ARCTURUS

Phase 1/2 Not yet recruiting

66 enrolled

Tumor-Agnostic

Neoplasms

NCT05754840 2025-05-29

CAN-PONC

Phase 1/2 Not yet recruiting

60 enrolled

Marijuana Abuse, Neoplasms

NCT05275374 2025-04-10

ENHANCE

Phase 1/2 Not yet recruiting

221 enrolled

DermatologicGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms

NCT05896371 2025-03-30

PRODIGY-1

Phase 1/2 Not yet recruiting

500 enrolled

Genitourinary

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT06896552 2025-03-26

Single-Center Trial on Ketogenic Diet and Immunotherapy in Advanced Cancer This Study Evaluates the Safety and Effects of a Ketogenic Diet (KD) Combined With Immunotherapy in Adults With Advanced Melanoma, cSCC, or RCC.

Phase 1/2 Not yet recruiting

60 enrolled

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Neoplasms

NCT06827080 2025-02-14

Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Not yet recruiting

15 enrolled

Tumor-Agnostic

Neoplasms

NCT06783153 2025-01-20

Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients

Phase 1/2 Not yet recruiting

80 enrolled

GastrointestinalGenitourinary

Neoplasms, Prostatic Neoplasms, Rectal Neoplasms

NCT06456138 2024-06-13

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

Phase 1/2 Not yet recruiting

60 enrolled

Tumor-Agnostic

Neoplasms

NCT05581875 2022-10-17

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory

Phase 1/2 Not yet recruiting

48 enrolled

Plasma cell

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell

Clinical Trials

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

ChefHat-001

Study of the Safety and Efficacy of DS010 in Patients With Cancer Cachexia

Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)

Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors

(BLOOM)

OP-NEU-101

A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors

FORCE

BCG-TIME

ARCTURUS

CAN-PONC

ENHANCE

PRODIGY-1

Single-Center Trial on Ketogenic Diet and Immunotherapy in Advanced Cancer This Study Evaluates the Safety and Effects of a Ketogenic Diet (KD) Combined With Immunotherapy in Adults With Advanced Melanoma, cSCC, or RCC.

Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer

Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory